Silence Therapeutics plc (SLN) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

Silence Therapeutics PLC ADR Annual stock financials by MarketWatch. View the latest SLN financial statements, income statements and financial ratios.

We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) stands against other takeover ...

Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic ...

Silence Therapeutics PLC Sponsored ADR (SLN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...

Shares of Silence Therapeutics PLC Sponsored ADR (SLN) have gained 52% over the past four weeks to close the last trading session at $5.41, but there could still be a solid upside left in the stock if ...

Women with endometrial cancer who are found to have lymph-node-positive disease during surgical staging by lymphadenectomy benefit from adjuvant chemotherapy; however, the remaining 78% of women who ...

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of ...